Vanberra Signal

Inform Genomics

Curated by Signal

Provider of pharmacogenomics tools for cancer

Overview

Provider of pharmacogenomics tools for cancer. The cloud-based platform uses advanced machine-learning algorithms to correlate interactions of SNPs and genes to predict clinical outcomes. It is developing two products. The first attempts to analyze patient genomic data and predict the percentage of patients receiving hematopoeitic stem cell transplants who will develop oral mucositis as a side-effect. The other product OnPART (Oncology Preferences And Risk of Toxicity) uses patient genomic data to predict response to chemotherapy and can be used by oncologists to pick the most effective chemotherapy agents for solid tumors.

Key facts

Founded
2010

Business model

More on Vanberra Signal

Members only

Competitors & similar companies

More Life Sciences Technology companies
  • Diagnostics, theranostics & therapeutics using proprietary drug discovery platform

    Life Sciences TechnologyFramingham, United States
  • Provider of mobile app and testing kits for the detection of COVID-19 ( SARS-CoV-2 )

    Life Sciences TechnologyStafford, United States
  • Artificial Intelligence based Artificial Pancreas System

    Life Sciences TechnologyAsheville, United States

About Inform Genomics

What does Inform Genomics do?

Provider of pharmacogenomics tools for cancer.

Where is Inform Genomics headquartered?

Inform Genomics is headquartered in Boston, United States.

When was Inform Genomics founded?

Inform Genomics was founded in 2010.

Which sector is Inform Genomics in?

Inform Genomics operates in Life Sciences Technology.

Who are Inform Genomics's competitors?

Companies similar to Inform Genomics include BERG Health, MobileDetectBIO, and Ideal Medical Technologies.